SCS Hf 10 Burst denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for scs hf10 burst are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies HF10/Burst SCS as Duplicate Therapy

Aetna may issue a duplicate-therapy denial for high-frequency (HF10) or burst-pattern spinal cord stimulation (SCS) when the patient is already receiving — or has recently received — another form of neuromodulation or interventional pain treatment. Common scenarios include: a prior or concurrent conventional SCS device, an intrathecal drug delivery system, or recent implantation of another neurostimulation device. Aetna's utilization management logic flags these as potentially overlapping, and the denial asserts that the requested therapy duplicates a benefit already being received.

## Why This Denial Is Appealable

HF10 and burst SCS use distinct stimulation parameters and mechanisms compared to conventional low-frequency SCS and other neuromodulation approaches. The clinical distinction between these modalities is recognized in peer-reviewed pain medicine literature and by relevant specialty society guideline organizations. If the prior or concurrent therapy is different in mechanism, has failed, or has been discontinued, the duplicate-therapy characterization is factually incorrect and should be contested.

## Federal Appeal Framework

• Internal appeal: File within your plan's deadline. Focus the appeal on the clinical and technical distinction between the proposed therapy and the one Aetna considers duplicative.
• Peer-to-peer review: Request a peer-to-peer call between the implanting physician and Aetna's medical reviewer to clarify the technical and clinical differences between therapies.
• External review (ACA §2719 / ERISA §503): If internal appeal is denied, request IRO review within 4 months. The IRO can evaluate whether Aetna's duplicate-therapy determination is consistent with accepted clinical standards.
• Expedited review: Available if the patient's pain condition constitutes a clinical urgency.

## Documentation to Gather

1. Prior device/therapy history — records confirming the prior therapy: device type, implant date, stimulation parameters used, clinical response, and current status (active, removed, failed, or discontinued). 2. Clinical distinction letter — a detailed letter from the pain physician or neurosurgeon explaining why HF10/burst SCS is not duplicative: the different mechanism of action, the clinical rationale for selecting this modality, and why the prior therapy does not address the same need. 3. Failed prior therapy documentation — if the prior or concurrent therapy failed or was inadequate, provide dated chart notes documenting the failure and the clinical basis for the new approach. 4. Diagnosis and functional status — records showing the current pain diagnosis, functional impact, and the clinical necessity for a distinct treatment approach. 5. Device-specific prescribing/coverage documentation — relevant sections of the Aetna coverage policy and the device labeling clarifying that these are distinct technologies.

## Criteria-Mapping Strategy

Obtain Aetna's published medical policy for spinal cord stimulation and neuromodulation. Identify the specific language used to define "duplicate therapy" and demonstrate, with clinical evidence, that HF10/burst SCS falls outside that definition as applied to this patient's situation.